Clinical trial Recruiting at 1 site Interventional Ages 18 to 75

Using a Regenerative Peripheral Nerve Interface to Improve Control of Lower Limb Prostheses

Official title: Regenerative Peripheral Nerve Interfaces to Enhance Function and Sensation in People With Transfemoral Amputation

Run by University of Michigan · NCT06275282 · Data updated 2026-11-12

This study is testing whether a new nerve interface can help people with above-knee amputations have better control and feeling in their robotic legs.

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment3 (estimated)
SponsorUniversity of Michigan
Academic / other
Locations1 site (Ann Arbor, Michigan)
StatusRecruiting
StartedFebruary 13, 2025
Main results expectedJune 30, 2027
Study endsSeptember 30, 2027
Registry record updatedMay 19, 2026
Trial IDNCT06275282 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals with unilateral above-knee amputations who have sufficient soft tissue quality and meet specific mobility criteria.

Probably not a fit

Patients with severe pain syndromes or significant scarring from injuries may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of a Regenerative Peripheral Nerve Interface (RPNI) to enhance the control and sensory feedback of advanced robotic limbs for individuals with above-knee amputations. The RPNI involves implanting a peripheral nerve into a free muscle graft, allowing for the generation of high-fidelity motor control signals and meaningful sensory feedback. The study aims to evaluate the stability and specificity of electromyography signals from the RPNI over a year following surgery. By addressing the limitations of current prosthetic devices, this approach seeks to improve the quality of life for amputees.

Why it matters

Potential benefit: If successful, this approach could significantly enhance the control and functionality of prosthetic limbs for individuals with above-knee amputations.

How similar studies have gone: While the concept of biologic interfaces is emerging, this specific application of RPNI for prosthetic control is novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Unilateral amputation of the leg proximal to the knee at least 6 months prior to enrollment.
* Low surgical risk (American Society of Anesthesiologists Class I and II).
* For participants without existing RPNI grafts (at the time of enrollment), the residual limb must have sufficient soft tissue quality to support performance of the RPNI operative procedures. Participants sustaining severe crushing or avulsion injuries with substantial superficial and deep scarring may not be appropriate candidates for inclusion in the study.
* Amputee Mobility Predictor with prosthesis (AMPPRO) score of at least 37 (Gailey et al. 2002).
* Sufficient clearance to a motorized prosthetic leg without the necessity for shoe lifts or extenders on the contralateral limb.

Exclusion Criteria:

* Severe pain syndrome including complex regional pain syndrome or severe phantom pain. All of these conditions would suggest pathological activity of the nerve and would exclude the participant from participation.
* Untreated mental health disorders and if they have any DSM-5 diagnoses, they must receive approval to participate from their mental health professional.
* Any medical conditions that, in the opinion of the Principal Investigator, would place them at high risk for a surgical procedure including recent myocardial infarction, cerebrovascular accidents, deep venous thrombosis, pulmonary embolus, uncontrolled diabetes, or end stage renal disease.
* Participants must not have used tobacco for at least one month prior to enrollment in the study.
* Participants must agree to not use tobacco for the duration of the study.
* Pregnancy.
* No other indwelling electronic implants like pacemakers, implantable cardioverter defibrillators, implantable neurostimulators, body worn insulin pumps, or body worn patient monitoring devices.
* Severe peripheral vascular occlusive disease, venous hypertension of the extremity, or severe lymphedema of the extremity.
* An autoimmune condition which is not well controlled by medication.
* A significant injury of the contralateral limb.
* Significant, uncorrected vision problems.
* Impaired mental capacity that negatively impacts verbal communication with the clinicians and research team or requires a Legally Authorized Representative to facilitate communication.

Where it's running

  • University of Michigan
    Ann Arbor, Michigan, United States
    Recruiting

Study contacts

  • Principal investigator: Deanna Gates, PhD — University of Michigan
  • Study coordinator: Deanna Gates, PhD
  • Email: gatesd@umich.edu
  • Phone: 734-647-2698

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.